During the past decade, Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 8 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo." #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Celgene" with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "Prof. Dr. M. Dreyling (co-chairman)" with 2 trials sponsored and "Celgene Corporation" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo." #1 collaborator was "Celgene Corporation" with 2 trials as a collaborator, "ClinAssess GmbH" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "AbbVie (prior sponsor, Abbott)" with 1 trials as a collaborator and "GELARC Service de Pharmacovigilance, Pierre Benite" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo." are "Chronic Lymphocytic Leukemia" (3 trials), "Multiple Myeloma" (3 trials), "Mantle Cell Lymphoma" (2 trials), "Myelodysplastic Syndromes" (2 trials) and "Acute Myelogenous Leukemia" (1 trials). Many other conditions were trialed in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo." in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo." are "Drug" (25 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (6 trials), "Cyclophosphamide" (4 trials), "Obinutuzumab" (4 trials), "Atezolizumab" (3 trials) and "Bendamustine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo." are 26 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., 4 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".